Twist Bioscience Corporation
NASDAQ:TWSTMedical - Diagnostics & Research
+$2.15 today
- Market cap
- $7.66B
- Beta
- 2.21
- P/E (TTM)
- -64.5
- EPS (TTM)
- -$1.32
Volume 2.23M
Average 1.53M
TWST Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Twist Bioscience CorporationNASDAQ: TWST
Selling, General & Admin · Q4 FY2026 · quarter ended Sep 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q4 FY2026 selling, general & admin of $74.68M rose 17.1% year over year, behind the +22.0% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 7.5% from the prior quarter. Over 3 fiscal years it compounded at +16.7% a year.
Context
- Selling, general & admin amounted to 65.6% of revenue in FY2026, unchanged from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $425.86M (+41.4%) for the fiscal year ending Sep 2027, a step up from the +22.0% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $74.68M-7.5% QoQ
- Last fiscal yearSep 2026
- $301.22M+22.0% YoY
- LTMSep 2026
- $301.22M+22.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2026
- 301.22M USD
- Year-over-year change
- +22.0%
- 4-year CAGR
- +9.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 301.22M | +22.0% |
| FY2025 | 2025-09-30 | 246.98M | +13.1% |
| FY2024 | 2024-09-30 | 218.4M | +15.1% |
| FY2023 | 2023-09-30 | 189.74M | -10.9% |
| FY2022 | 2022-09-30 | 212.95M | — |
Selling, General & Admin vs competitors
How TWST compares with its peers on the latest reported figures
- TWST's LTM Sep 2026 selling, general & admin of $301.22M is the highest of the 2 companies compared; the peer median is $289.52M.
- Its year-over-year change of +22.0% is the highest of 2, against a peer median of +3.9%.
- Selling, general & admin amounts to 65.6% of revenue for TWST, versus a peer median of 36.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $301.22M | +22.0% | +16.7% | 65.6% | |
| LTM Jun 2026 | $289.52M | +3.9% | +10.4% | 36.9% | |
| Peer median (excluding TWST) | $289.52M | +3.9% | +10.4% | 36.9% | |
Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Revenue | 203.57M | 245.11M | 312.97M | 376.57M | 459.43M |
| Cost of Revenue | 119.33M | 155.38M | 179.63M | 185.57M | 218.63M |
| Gross Profit | 84.24M | 89.73M | 133.35M | 191M | 240.8M |
| Gross Margin | 41.4% | 36.6% | 42.6% | 50.7% | 52.4% |
| Research & Development | 120.31M | 106.89M | 90.85M | 80.29M | 71.84M |
| Selling, General & Admin | 212.95M | 189.74M | 218.4M | 246.98M | 301.22M |
| Operating Expenses | 319.01M | 306.89M | 354.18M | 327.26M | 380.26M |
| Depreciation & Amortization | 16.51M | 29.31M | 31.43M | 24.85M | 0 |
| EBITDA | (211.68M) | (174.15M) | (176.71M) | (52.1M) | (129.8M) |
| EBITDA Margin | -104.0% | -71.1% | -56.5% | -13.8% | -28.3% |
| Operating Income | (234.78M) | (217.16M) | (220.83M) | (136.26M) | (139.46M) |
| Operating Margin | -115.3% | -88.6% | -70.6% | -36.2% | -30.4% |
| Interest Income | 3.06M | 14.37M | 15.34M | 11.36M | 8.8M |
| Interest Expense | 80K | 5K | 29K | 0 | 0 |
| Other Income / Expenses | 6.5M | 13.69M | 12.67M | 59.31M | 8.85M |
| Income Before Tax | (228.27M) | (203.47M) | (208.17M) | (76.95M) | (130.61M) |
| Pre-Tax Margin | -112.1% | -83.0% | -66.5% | -20.4% | -28.4% |
| Income Tax Expense | (10.41M) | 1.15M | 560K | 719K | (406K) |
| Net Income | (217.86M) | (204.62M) | (208.73M) | (77.67M) | (130.2M) |
| Net Margin | -107.0% | -83.5% | -66.7% | -20.6% | -28.3% |
| EPS (Basic) | (4.04) | (3.60) | (3.60) | (1.30) | (2.08) |
| EPS (Diluted) | (4.04) | (3.60) | (3.60) | (1.30) | (2.08) |
| Weighted Avg Shares | 53.89M | 56.89M | 58.02M | 59.81M | 62.62M |
| Weighted Avg Shares (Diluted) | 53.89M | 56.89M | 58.02M | 59.81M | 62.62M |
Twist Bioscience Corporation
NASDAQ:TWST
Intrinsic Alpha fair value
Locked
Current Price
$116.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.